China Resources Pharmaceutical Group Limited clinical trials

The registry lists 69 studies whose lead sponsor is China Resources Pharmaceutical Group Limited or one of 8 companies grouped under it. 23 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 69. Browse all 69 →

• Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUreRecruitingNCT07687186Phase 3

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted after Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Study of B2065 in Patients With Acute Ischemic StrokeRecruitingNCT07371624Phase 1/2

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted after Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Study of the Effectiveness and Safety of JS1-1-01 Tablet in Patients With Moderate to Severe DepressionNot yet recruitingNCT07485595Phase 2/3

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted after Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMDNot yet recruitingNCT07269769Phase 3

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted after Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary EfficacyRecruitingNCT07514065Phase 1

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted after Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Clinical Trial of P134 Cells in Recurrent GlioblastomaRecruitingNCT07318818Phase 1/2

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted after Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress SyndromeRecruitingNCT06696261Phase 3

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs for the Treatment of Chronic Heart FailureRecruitingNCT07265349Phase 1/2

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted after Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）RecruitingNCT07128797Phase 1

  Sponsor listed in the registry: Tasly Biopharmaceuticals Co., Ltd. · First submitted after Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited

• Phase III Trial of Susu Zhike Granules in Children With Cold-cough Syndrome for Acute Cough TreatmentNot yet recruitingNCT06773117Phase 3

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable AnginaRecruitingNCT03789552Phase 3

  Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited

• A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal CancerNot yet recruitingNCT06838546Phase 2

  Sponsor listed in the registry: Tasly Biopharmaceuticals Co., Ltd. · First submitted before Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited

• Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)Not yet recruitingNCT06753890Phase 3

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid TumorsNot yet recruitingNCT06724263Phase 2

  Sponsor listed in the registry: Tasly Biopharmaceuticals Co., Ltd. · First submitted before Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited

• A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and PlaceboRecruitingNCT06000956Phase 3

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common ColdRecruitingNCT06697886Phase 3

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary GlandsRecruitingNCT06685978Phase 3

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• Efficacy and Safety of Jia Shen Tablets in Chronic Heart FailureNot yet recruitingNCT06669169Phase 2

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque PsoriasisRecruitingNCT06058546Phase 2

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR)RecruitingNCT05632861Phase 2

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• Pharmacokinetic and Pharmacodynamic of Jia Shen Tablets in Chronic Heart FailureRecruitingNCT06348498Phase 1

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA MutationsRecruitingNCT05420779Phase 2

  Sponsor listed in the registry: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. · First submitted before Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. became part of China Resources Pharmaceutical Group Limited

• A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid TumorsNot yet recruitingNCT05650385Phase 1

  Sponsor listed in the registry: Tasly Biopharmaceuticals Co., Ltd. · First submitted before Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited

• Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)CompletedNCT06006689Phase 2

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart FailureCompletedNCT04983043Phase 2

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection FractionCompletedNCT04944706Phase 2

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease PsychosisCompletedNCT06068465Phase 3

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid TumorsCompletedNCT06238687Phase 1/2

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty ArthritisCompletedNCT06068478Phase 3

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe DepressionCompletedNCT06259526Phase 2

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Study of the Safety,Tolerability,and Pharmacokinetics of Multiple-Ascending Dose JS1-1-01 in Healty Subjects.CompletedNCT05656274Phase 1

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Study of Xiangjurupining Capsule in the Treatment of Hyperplasia of Breast (Liver Stagnation and Phlegm Coagulation)CompletedNCT04229706Phase 2

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)CompletedNCT04492787Phase 2

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• Efficacy and Safety of Susu Zhike Granules for Treating Acute Cough Due to Common Cold With Cold-cough Syndrome in ChildrenCompletedNCT04457011Phase 2

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)CompletedNCT04993729Phase 3

  Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited

• rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)CompletedNCT05700591Phase 3

  Sponsor listed in the registry: Tasly Biopharmaceuticals Co., Ltd. · First submitted before Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited

• Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19No longer availableNCT04646031

  Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited

• A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy SubjectsStatus unknownNCT05655221Phase 1

  Sponsor listed in the registry: Tasly Biopharmaceuticals Co., Ltd. · First submitted before Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited

• A Trial of CRB4101 in Healthy SubjectsStatus unknownNCT05641181Phase 1

  Sponsor listed in the registry: China Resources Biopharmaceutical Co., Ltd

• A Phase Ⅱ Clinical Study of Sanhuangjingshimingwan in Wet( Neovascular)Age-related Macular Degeneration(wAMD) SubjectsCompletedNCT04486963Phase 2

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Study to Evaluate the Tolerability and Pharmacokinetics of Jiashen Tablets in Healthy SubjectsCompletedNCT04164290Phase 1

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• Study of Jitongning Tablet to Treat SpondyloarthritisCompletedNCT03932019Phase 2

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• A Real World Study of the Treatment of Gastric Adenocarcinoma With HuachansuStatus unknownNCT05249244

  Sponsor listed in the registry: China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

• A Clinical Study to Evaluate the Safety and Efficacy of T92 in Pediatric Patients With Tourette SyndromeStatus unknownNCT05188274Not applicable

  Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited

• Evaluate the Efficacy, Safety and Tolerability of TSUPPORT for Adults With Tourette SyndromeStatus unknownNCT05183594Not applicable

  Sponsor listed in the registry: Tasly Pharmaceuticals, Inc. · First submitted before Tasly Pharmaceuticals, Inc. became part of China Resources Pharmaceutical Group Limited

• Exploratory Study on Dosage of Qizhi Weitong Granules in the Treatment of Irritable Bowel Syndrome （IBS)Status unknownNCT05113888Phase 2

  Sponsor listed in the registry: China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

• Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLCStatus unknownNCT05098990Phase 4

  Sponsor listed in the registry: China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

• A Study of Qishenyiqi Dripping Pills in Healthy ParticipantsCompletedNCT04471298Phase 1

  Sponsor listed in the registry: Tasly Pharmaceutical Group Co., Ltd · First submitted before Tasly Pharmaceutical Group Co., Ltd became part of China Resources Pharmaceutical Group Limited

• Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis (AS).Status unknownNCT04934059Phase 4

  Sponsor listed in the registry: China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

• A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary EmbolismCompletedNCT03108833Phase 2

  Sponsor listed in the registry: Tasly Biopharmaceuticals Co., Ltd. · First submitted before Tasly Biopharmaceuticals Co., Ltd. became part of China Resources Pharmaceutical Group Limited